Drew Ranieri
Stock Analyst at Morgan Stanley
(1.26)
# 3,725
Out of 5,138 analysts
170
Total ratings
46.74%
Success rate
-11.06%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $17.44 | +31.88% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $92.46 | +8.15% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $15.95 | +31.66% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $3.87 | +55.04% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $359.39 | +23.82% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $12.53 | +115.48% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $2.70 | +196.30% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $20.46 | +7.53% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $16.75 | -52.24% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $5.48 | +1,405.47% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $24.20 | +57.02% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $75.73 | +26.77% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.87 | +119.04% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $207.42 | +42.22% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $103.05 | +171.71% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $7.74 | -35.40% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $19.84 | +252.82% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $546.76 | -45.13% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $17.44
Upside: +31.88%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $92.46
Upside: +8.15%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $15.95
Upside: +31.66%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $3.87
Upside: +55.04%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $359.39
Upside: +23.82%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $12.53
Upside: +115.48%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $2.70
Upside: +196.30%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $20.46
Upside: +7.53%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $16.75
Upside: -52.24%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $5.48
Upside: +1,405.47%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $24.20
Upside: +57.02%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $75.73
Upside: +26.77%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.87
Upside: +119.04%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $207.42
Upside: +42.22%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $103.05
Upside: +171.71%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $7.74
Upside: -35.40%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $19.84
Upside: +252.82%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $546.76
Upside: -45.13%